Abstracts tagged "Outcome measures"

Abstract Number: 0977 • ACR Convergence 2023
Prevalence of Arthritis in the United States: National Estimates from a Population-based Study
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Arthritis is the number 1 cause of disability among U.S. adults and reported to cost > $300 billion in direct and indirect costs in…
Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
Abstract Number: 1512 • ACR Convergence 2023
Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial
Khaled Mahmoud, Michelle Wilson, Md Yuzaiful Md Yusof, Sarah Brown, Elizabeth Hensor and Ed Vital, University of Leeds, Leeds, United Kingdom
Background/Purpose: New medicines in SLE have not met endpoints in placebo-controlled RCTs when other evidence indicates they are effective. Reasons suggested are inclusion of patients…
Abstract Number: 1874 • ACR Convergence 2023
Cartilage Thickness Measures Are More Responsive Than Cartilage Area Loss Measures: A Comparison of Quantitative and Semi-quantitative Cartilage Assessments from the Osteoarthritis Initiative
Aaron Ray¹, Alan Brett², Bright Dube³, Michael Bowes⁴ and Philip Conaghan³, ¹York and Scarborough Teaching Hospitals: NHS Foundation Trust, York, United Kingdom, ²Stryker, Austin, TX, ³University of Leeds, Leeds, United Kingdom, ⁴Imorphics Ltd, Manchester, United Kingdom
Background/Purpose: Cartilage loss in 1-2 year osteoarthritis clinical trials is often small, but a critical outcome measure. The aim of this study was to compare…
Abstract Number: 2233 • ACR Convergence 2023
Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials
Thomas Macleod¹, Xenofon Baraliakos², Emmanouil Rampakakis³, Warner Chen⁴, Antonius Pieter J Van Den Heuvel⁴, Loqmane Seridi⁴, May Shawi⁵, Frederic Lavie⁶, Joseph F. Merola⁷, Proton Rahman⁸ and Dennis McGonagle⁹, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁴Translational Sciences, Janssen Research & Development, LLC, Spring House, PA, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁹Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Neutrophils have potential pathogenic roles in chronic inflammatory diseases (e.g., neutrophilic cutaneous microabscesses in psoriasis, and neutrophils in the synovial fluid/tissue in PsA and…
Abstract Number: 2501 • ACR Convergence 2023
Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity
Jingru Tian¹, Shuntong Kang², Dingyao Zhang³ and Qianjin Lu⁴, ¹Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Nanjing, China, ³Graduate Program in Biological and Biomedical Sciences, Yale University, New Haven, CT, ⁴Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a common multisystem autoimmune disease with chronic inflammation. Many efficacy evaluation indicators of randomized clinical trials (RCTs) for SLE…
Abstract Number: 0166 • ACR Convergence 2023
Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States
Zhiyi Li¹, Elizabeth Marchlewicz², Danae Black², Hana Schwartz², Yang Zhao¹ and Erik Imel³, ¹Kyowa Kirin North America, Bedminster, NJ, ²Merative, Cambridge, MA, ³Indiana University School of Medicine, Indianapolis, IN
Background/Purpose: Familial hypophosphatemia (FH) is most commonly due to phosphate regulating endopeptidase X-linked (PHEX) gene mutations resulting in renal phosphate wasting, which leads to rickets,…
Abstract Number: 0441 • ACR Convergence 2023
Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Dimitrios Pappas¹, Jacqueline O’Brien¹, Lin Guo¹, Ying Shan¹, Joshua Baker², Gregory Kricorian³, Scott Stryker⁴ and David Collier³, ¹CorEvitas, LLC, Waltham, MA, ²University of Pennsylvania, Philadelphia, PA, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA
Background/Purpose: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as…
Abstract Number: 1006 • ACR Convergence 2023
Use of Implementation Strategies to Promote Adherence of Knee Osteoarthritis Guidelines and Improve Patient Outcomes: A Systematic Review
Michelle Ramirez¹, Rebecca Fillipo¹, Connor Drake¹, Lesley Skalla², Kelli Allen³, Amanda Nelson⁴ and Maggie Horn¹, ¹Duke University School of Medicine, Durham, NC, ²Duke University Medical Center Library & Archives, Durham, NC, ³University of North Carolina, Durham, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Despite the development of care models and practice guidelines the translation of knee osteoarthritis guidelines to practice remains suboptimal. Theoretically informed implementation strategies may…
Abstract Number: 1264 • ACR Convergence 2023
Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study
Martina Skacelova¹, Ondrej Janca², Milos Kudelka², Bishu Shrestha³, Pavel Horak⁴ and Eva Kriegova³, ¹Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic, ²Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic, ³Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic, Olomouc, Czech Republic, ⁴Department of Internal Medicine III- Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Although telemedicine in rheumatoid arthritis (RA) could improve disease control with lower healthcare costs, knowledge of suitable parameters for self-testing disease activity still remains…
Abstract Number: 1515 • ACR Convergence 2023
Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
Dinesh Khanna¹, Christopher Denton², Masataka Kuwana³, Daniel Furst⁴, Suiyuan Huang¹, Barbara White⁵ and Robert Spiera⁶, ¹University of Michigan, Ann Arbor, MI, ²University College London, London, United Kingdom, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴University of California Los Angeles, Los Angeles, CA, ⁵SFJ Pharmaceuticals, Towson, MD, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: Revised CRISS has been proposed an approvable outcome measure in early diffuse cutaneous SSc (dcSSc)1. The index is undergoing the FDA review as part…
Abstract Number: 1901 • ACR Convergence 2023
Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Ørnbjerg¹, Brigitte Michelsen², Tore Kvien³, Daniela Di Giuseppe⁴, Johan Karlsson Wallman⁵, Jakub Zavada⁶, Sella Provan⁷, Ana Maria Rodrigues⁸, Maria Jose Santos⁹, Ziga Rotar¹⁰, Dan Nordstrom¹¹, Anna-Mari Hokkanen¹², Gary Macfarlane¹³, Gareth T. Jones¹³, Irene van der Horst-Bruinsma¹⁴, Pasoon Hellamand¹⁵, Mikkel Østergaard¹⁶ and Merete Hetland¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ³Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁷Diakonhjemmet Hospital, Oslo, Norway, ⁸Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ⁹Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Helsinki University and Helsinki University Hospital, Helsinki, Finland, ¹³Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹⁴Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands, ¹⁵Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: When assessing disease activity in patients with axial spondyloarthritis (axSpA), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over ASDAS…
Abstract Number: 2262 • ACR Convergence 2023
Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study
Kathryn Connelly¹, Rachel Koelmeyer¹, Darshini Ayton¹, Raychel Barrallon¹, Laura Eades², Vera Golder³, Kate gregory¹, John May¹, Rangi Kandane-Rathnayake³, Maisarah Mydin¹, Munni Akther¹, Afia Anzum¹, Jeanette Andersen⁴, Hermine Brunner⁵, Cynthia Aranow⁶, Laurent Arnaud⁷, Anca Askanase⁸, Catherine Barbey⁹, Joy Buie¹⁰, Laurie Burke¹¹, Alain Cornet¹², Karen Costenbader¹³, Maria Dall'Era¹⁴, Joan Merrill¹⁵, Khadija Dantata¹⁶, Alan Friedman¹⁷, Richard Furie¹⁸, Sandra Garces¹⁹, Maja Hojnik²⁰, Kenneth Kalunian²¹, Justine Maller²², Patrick Marquis²³, Marta Mosca²⁴, Erika Noss²⁵, Guillermo Pons-Estel²⁶, Lee Simon²⁷, Eve Smith²⁸, Alessandro Sorrentino²⁹, Anna Stevens³⁰, George Stojan³¹, Ying Sun³², Yoshiya Tanaka³³, Ed Vital³⁴, Ronald van Vollenhoven³⁵, Victoria P. Werth³⁶ and Eric Morand³⁷, ¹Monash University, Clayton, Australia, ²Monash Health and Monash University, Clayton, Australia, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Lupus Europe, Knebel, Denmark, ⁵Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷University Hospitals of Strasbourg, Strasbourg, France, ⁸Columbia University Medical Center, New York, NY, ⁹Biogen, Baar, Switzerland, ¹⁰Lupus Foundation of America, York, SC, ¹¹LORA Group, Normal, IL, ¹²Lupus Europe, Brussels, Belgium, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Lupus Foundation of America, Richmond Hill, GA, ¹⁷AbbVie, Inc., North Chicago, IL, ¹⁸Northwell Health, Manhasset, NY, ¹⁹Amgen, Inc., Thousand Oaks, CA, ²⁰Eli Lilly and Company, Indianapolis, IN, ²¹University of California San Diego, La Jolla, CA, ²²Genentech, Inc., Half Moon Bay, CA, ²³Modus Outcomes, Newton, MA, ²⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²⁵Janssen Research and Development, Dresher, PA, ²⁶CREAR, Rosario, Argentina, ²⁷SDG LLC, West Newton, MA, ²⁸University of Liverpool, Liverpool, United Kingdom, ²⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ³⁰Bristol Myers Squibb, Groton, CT, ³¹UCB, Baltimore, MD, ³²the healthcare business of Merck KGaA, Darmstadt, Germany, ³³University of Occupational and Environmental Health, Kitakyushu, Japan, ³⁴University of Leeds, Leeds, United Kingdom, ³⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ³⁶University of Pennsylvania, Wynnewood, PA, ³⁷Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: The Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE) is a novel clinical outcome assessment (COA) for SLE randomized controlled trials (RCTs), being developed…
Abstract Number: 2522 • ACR Convergence 2023
Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Primary total hip arthroplasty (THA) patients often have concomitant medical comorbidities. This study aims to identify the impact of diabetes mellitus (DM) on inpatient…
Abstract Number: 0176 • ACR Convergence 2023
Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Social determinants of health (SDOH) have a significant impact on the health outcomes of many chronic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].